Prolyl-specific peptidases and their inhibitors in biological processes

Current Chemical Biology

Volumn 2, Issue 2, 2008, Pages 97-109

  Juillerat Jeanneret, Lucienne ^a  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Cancer; Diabetes; Dipeptidyl peptidase; Fibroblast activation protein; Inflammation; Inhibitors; Neurodegeneration; Prolyl oligopeptidase; Prolyl specific proteases; Seprase

Indexed keywords

1 [N (4 CHLOROBENZYL)SUCCINAMOYL]PROLINAL; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ABT 279; AMYLOID BETA PROTEIN; ANTIDIABETIC AGENT; CYTOKINE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8 INHIBITOR; DIPEPTIDYL PEPTIDASE 9 INHIBITOR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; EXOPEPTIDASE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLYCINE DERIVATIVE; N BENZYL 2 [[2 (HYDROXYACETYL) 1 PYRROLIDINYL]CARBONYL] 1 PYRROLIDINECARBOXAMIDE; PRODRUG; PROLINE IMINOPEPTIDASE; PROLINE IMINOPEPTIDASE INHIBITOR; PROLYL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE INHIBITOR; PROTEIN INHIBITOR; PROTEINASE; S 17092 1; SAXAGLIPTIN; SEPRASE; SITAGLIPTIN; SUAM 1221; UNINDEXED DRUG; VILDAGLIPTIN;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; COGNITIVE DEFECT; CROHN DISEASE; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GLIOBLASTOMA; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MEMORY DISORDER; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ANIMALIA; MAMMALIA;

EID: 48249130118     PISSN: 18723136     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231308784220563     Document Type: Review

References (174)

1. Yaron A, Naider F. Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 1993; 28: 31-81.
2. Busek P, Malik R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 2004; 36: 408-421.
3. Chen WT, Kelly T, Ghersi G. DPPIV, seprase and related serine peptidases in multiple cellular functions. Curr Topics Dev Biol 2003; 54: 207-232.
4. Chen WT. DPPIV and seprase in cancer invasion and angiogenesis. Adv Exp Med Biol 2003; 524: 197-203.
5. Ghersi G, Dong H, Goldstein LA, et al. Seprase-dPPIV association and prolyl peptidase and gelatinase activities of the protease complex. Adv Exp Med Biol 2003; 524: 87-94.
6. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Reg Pept 1999; 85: 9-24.
7. Mentlein R. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Exp Opin Invest Drugs 2005; 14: 57-64.
8. Polgar L. The prolyl oligopeptidase family. Cell Mol Life Sci 2002; 59: 349-362.
9. Rosenblum JS, Kosarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003; 7: 496-504.
10. Cunningham DF, O'Connor B. Proline specific peptidases. Biochim Biophys Acta 1997; 1343: 160-186.
11. Sedo A, Malik R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?. Biochim Biophys Acta 2001; 1550: 107-116.
12. Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 2005; 7: 253-269.
13. Kelly T. Evaluation of seprase activity. Clin Exp Metastasis 1999; 17: 57-62.
14. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994; 15: 180-184.
15. De Meester I, Lambeir AM, Proost P, Scharpé S. Dipeptidyl peptidase IV substrates. Adv Exp Med Biol 2003; 524: 3-17.
16. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Science 2005; 108: 277-292.
17. Leiting B, Pryor KD, Wu JK, et al. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J 2003; 371: 525-532.
18. Evans DM. Dipeptidyl peptidase IV inhibitors. IDrugs 2002; 5: 577-585.
19. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004; 47: 4135-4141.
20. Deacon CF. MK-431 [Merck]. Curr Opin Invest Drugs 2005; 6: 419-426.
21. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-1670.
22. Holst JJ, Deacon CF. Glucagon-like peptides 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 2004; 4: 589-596.
23. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999; 274: 36505-36512.
24. Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Ent J Cancer 2001; 95: 67-72.
25. Huber MA, Kraut N, Park JE, et al. Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol 2003; 120: 182-188.
26. Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 2004; 64: 2712-2716.
27. Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN. A marker for neoplasic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 1993; 177: 1135-1143.
28. Scott AM, Wiseman G, Welt S, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003; 9: 1939-1647.
29. Pineiro-Sanchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Chen WT. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem 1997-1272: 7595-7601.
30. Aimes RT, Zijlstra A, Hooper JD, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost 2003; 89: 561-572.
31. Iwasa S, Jin X, Okada K, Mitsumata M, Ooi A. Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett 2003; 199: 91-98.
32. Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 2003; 22: 259-269.
33. Okada K, Chen WT, Iwasa S, et al. Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer. Oncology 2003; 65: 363-370.
34. Goodman JD, Rozypal TL, Kelly T. Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis 2003; 20: 459-470.
35. Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodeling interface in human cirrhosis. Hepatology 1999; 29: 1768-1778.
36. Wang XM, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion and migration by the LX-2 human stellate cell line. Hepatology 2005; 42: 935-945.
37. Goldstein LA, Chen WT. Identification of an alternatively spliced seprase mRNA that encodes a novel intracellular isoform. J Biol Chem 2000; 275: 2554-2559.
38. Underwood R, Chiravuri M, Lee H, et al. Sequence, purification and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem 1999; 274: 34053-34058.
39. Maes MB, Lambeir AM, Gilany K, et al. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem J 2005; 386: 315-324.
40. Chiravuri M, Schmitz T, Yardley K, Underwood R, Dayal Y, Huber BT. A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-prohne cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J Immunol 1999; 163: 3092-3099.
41. Chiravuri M, Agarraberes F, Mathieu SL, Lee H, Huber BT. Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase. J Immunol 2000; 165: 5695-5702.
42. Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000; 267: 6140-6150.
43. Ajami K, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 2004; 1679: 18-28.
44. Olsen C, Wagtmann N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 2002; 299: 185-193.
45. Zhu H, Zhou ZM, Lu L, et al. Expression of a novel dipeptidyl peptidase 8 (DPP8) transcript variant, DPP8-v3, in human testis. Asian J Androl 2005; 7: 245-255.
46. Duke-Cohan JS, Go J, McLaughlin DF, Xu Y, Freeman GJ, Schlossman SF. Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. Proc Natl Acad Sci USA 1998; 95: 11336-11341.
47. SA-like properties. J Physiol 2005; 568: 767-788.
48. Pangalos MN, Neefs JM, Somers M, et al. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J Biol Chem 1999; 274: 8470-8483.
49. Gallagher PE, Tallant EA. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004; 25: 2045-2052.
50. De Mester I, Vanhoof G, Hendriks D, Demuth HU, Yaron A, Scharpé S. Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes, Clin Chim Acta 1992; 210:23-34.
51. Engel M, Hoffmann T, Wagner L, et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA 2003; 100: 5063-5068.
52. Hiramatsu H, Yamamoto A, Kyono K, et al. The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A. Biol Chem 2004; 385: 561-564.
53. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003; 10: 19-25.
54. Oefiner C, D'Arcy A, Mac Sweeney A, Pierau S, Gardiner R, Dale GE. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]- 2-cyano-(S)-pyrrolidine. Acta Crystallogr 2003; D59:1206-1212.
55. Thoma R, Löffler B, Stihle M, Huber W, Ruf A, Hennig M. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure 2003; 11: 947-959.
56. Edmondson SD, Mastracchio A, Beconi M, et al. Potent and selective proline derived dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2004; 14. 5151-5155.
57. Reinhold D, Bank U, Bühling F, et al. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production. Immunobiol 1993; 188: 403-414.
58. Reinhold D, Bank U, Bühling F, et al. Inhibitors of dipeptidyl peptidase IV (DPP IV, CD26) induce secretion of transforming growth factor β1 (TGF-βl) in stimulated mouse splenocytes and thymocytes. Immunol Lett 1997; 58: 29-35.
59. Reinhold D, Hemmer B, Gran B, et al. Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. J Neuroimmunol 1998; 87: 203-209.
60. Fülülop V, Böcskei Z, Polgar L. Prolyl oligopeptidase: an unusual β-propeller domain regulates proteolysis. Cell 1998; 94: 161-170.
61. Barelli H, Petit A, Hirschi E, et al. S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Biochem Biophys Res Comm 1999; 257: 657-661.
62. Jarho EM, Venalainen JI, Huuskonen J, et al. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J Med Chem 2004; 47: 5605-5607.
63. Jarho EM, Wallen EAA, Christiaans JA, et al. Dicarboxylic acid azacycle L-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme inhibitor interactions. J Med Chem 2005; 48: 4772-4782.
64. Venalainen JI, Wallen EA, Poso A, Garcia-Horsman JA, Mannisto PT. Synthesis and characterization of the novel fluorescent prolyl oligopeptidase inhibitor 4-fluoresceinthio-carbamoyl-6-aminocaproyl-L-p-lyl-2(S)-(hydroxyacetyl) pyrrolidine. J Med Chem 2005; 49: 7093-7095.
65. Jiaang WT, Chen YS, Hsu T, et al. Novel isoindoline compounds for potent and selective inhibition of prolyl dipepfidase DPP8. Bioorg Med Chem Lett 2005; 15: 687-691.
66. Xu J, Ok HO, Gonzalez EJ, Colwell LF, et al. Discovery of potent and selective beta-homophenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2004; 14: 4759-4762.
67. Xu J, Wei L, Madivink R, et al. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2005; 15: 2533-2536.
68. Zhao K, Lim DS, Funaki T, Welch JT. Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg Med Chem 2003; 11: 207-215.
69. Zhao G, Taunk PC, Magnin DR, et al. Diprolyl nitrites as potent dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2005; 15: 3992-3995.
70. Wallen EA, Christiaans JA, Jarho EM, et al. (2003) New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(L-prolylpyrrolidine) amides. J Med Chem 2003; 46: 4543-4551.
71. Reinhold D, Hemmer B, Gran B, et al. Dipeptidyl peptidase IV (CD26): role in T cell activation and autoimmune disease. Adv Exp Med Biol, 2000; 477: 155-160.
72. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54: 2988-2994.
73. Madar DJ, Kopecka H, Pireh D, et al. Discovery of 2-[4-{{2-(2S,5R)-cyano-5-ethynyl-1-pirrolodinyl]-2-oxoethyl]amino]-4- methyl-l-piperidinyl]-4-pyridinecarboxyclic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. J Med Chem 2006; 49: 6416-6420.
74. Yasuda N, Nagakura T, Inoue T, et al. E3024,3-but-2-ynyl-5-methyl- 2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor. Eur J Pharm 2006; 548: 181-187.
75. Soroka A, Van der Veken P, De Meester I, et al. Synthesis and dipeptidyl peptidase inhibition of N-(4-substitated-2,4-diaminobutanoyl)piperidines. Bioorg Med Chem Lett 2006; 16: 4777-4779.
76. Xu J, Wei L, Mathvink RJ, Edmondson SD, et al. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidise IV inhibitors. Bioorg Med Chem Lett 2006; 16: 5373-5377.
77. Gilmore BF, Lynas JF, Scott CJ, McGoohan C, Martin L, Walker B. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPα). Biochem Biophys Res Comm 2006; 346: 436-446.
78. Brandt I, Joossens J, Chen X, et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2- carbonitrile). Biochem Pharm 2005; 70: 143-143.
79. Cheon HG, Kim SS, Kim KR, et al. Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold. Biochem Pharm 2005; 70: 22-29.
80. Lu IL, Lee SJ, Tsu H, et al. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. Bioorg Med Chem Lett 2005; 15: 3271-3275.
81. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB. NVP-DPP728 (1- [2-[(5-cyanopyridin-2-yl)amino]ethyl]amino] acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochem 1999; 38: 11597-11603.
82. Ward RA, Perkins TDJ, Stafford J. Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors. J Med Chem 2005; 48: 6991-6996.
83. Hulin B, Cabral S, Lopaze MG, van Volkenburg MA, Andrews KM, Parker JC. New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2005; 15: 4770-4773.
84. Gabrilovac J, Abrami M, Uzarevi B, Andreis A, Poljak L. Dipeptidyl peptidase IV (DPPIV) enzyme activity on immature T-cell line R1.1 is down-regulated by dynorphin-A(1-17) as a non-substrate inhibitor. Life Sciences 2003; 73: 151-166.
85. Villhauer EB, Brinkman JA, Naderi GB, et al. 1- (3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-2789.
86. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoro-methyl)-5,6-dihydro[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141-151.
87. Wiedeman PE, Trevillyan JM. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Invest Drugs 2003; 4: 412-420.
88. Berger Y, Ingrassia L, Neier R, Juillerat-Jeanneret L. Evaluation of dipeptide derivatives of 5-aminolevulinic acid as precursors for photosensitizers in photodynamic therapy. Biorg Med Chem 2003; 11: 1343-1351.
89. Berger Y, Chapuis BC, Schmitt F, Neier R, Juillerat-Jeanneret L. Determination of intracellular prolyl/glycyl-specific proteases in intact living human cells using protoporphyrin IX production as a reporter system. ChemBiol 2005; 12: 867-872.
90. Hsiung HM, Smiley DL, Zhang XY, et al. Potent peptide agonists for human melanocortin 3 and 4 receptors derived from enzymatic cleavage of human β-MSH(5-22) by dipeptidyl peptidase I and dipeptidyl peptidase IV. Peptides 2005; 26: 1988-1996.
91. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetized pig. Diabetologia 2005; 48: 1882-1890.
92. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obesity Metab 2005; 7: 692-698.
93. Iwata S, Yamaguchi N, Munakata Y, et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999; 11: 417-426.
94. Iwata S, Morimoto C. CD26/dipeptidyl peptidase IV in context: the different roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med 1999; 190: 301-305.
95. Pethiyagoda CL, Welch DR, Fleming TP. Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin Exp Metastasis 2001; 18: 391-400.
96. Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol. Histopath 2004; 19: 1345-1351.
97. Wesley UV, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999; 190: 311-322.
98. Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 2004; 109: 855-866.
99. Aratake Y, Umeki K, Kiyoyama K, et al. Diagnostic utility of galectin-3 and CD26/DPP IV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopath 2002; 26: 366-372.
100. Lelièvre V, Caigneaux E, Muller JM, Falcon J. Extracellular adenosine deprivation induces epithelial differentiation of HT29 cells: evidence for a concomitant adenosine Al/A2 receptor balance regulation. Eur J Pharmacol 2000; 391: 21-29.
101. Bogenrieder T, Finstad CL, Freeman RH, et al. Expression and localization of aminopeptidase A, aminopeptidase N and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 1997; 33: 225-232.
102. Asada Y, Aratake Y, Kotani T, et al. Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma. Histopathology 1993; 23: 265-270.
103. Kajiyama H, Kikkawa F, Maeda O, Suzuki T, Ino K, Mizutani S. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology 2002; 63: 158-165.
104. Kajiyama H, Kikkawa F, Ino K, Shibata K, Mizutani S. Expression of CD26/ dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade. Adv Exp Med Biol 2003; 524: 245-248.
105. Kajiyama H, Kikkawa F, Kbin E, Shibata K, Ino, K, Mizutani S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 2003; 63: 2278-2283.
106. Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mitzutani S. Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 2005; 1751:45-51.
107. Cheng HC, Abdel-Ghany M, Zhang S, Pauli BU. Is the Fischer 344/CRJ rat a protein- knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer. Clin Exp Metastasis 1999; 17: 609-615.
108. Cheng HC, Abdel-Ghany M, Elble RC, Pauli BU. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem 1998; 273: 24207-24215.
109. Juillerat-Jeanneret L, Lohm S, Hamou MF, Pinet F. Regulation of aminopeptidase A in human brain tumor vasculature: evidence for a role of TGF-β. Lab Invest 2000; 80: 973-980.
110. Juillerat-Jeanneret L, Monnet-Tschudi F, Zürich MG, Lohm S, Duijvestijn AM, Honegger P. Regulation of peptidase activity in a three-dimensional aggregate model of brain tumor vasculature. Cell Tissue Res 2003; 311; 53-59.
111. Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res 2004; 64: 5471-5480.
112. Kornek B, Lassmann H. Neuropathology of multiple sclerosis- new concepts. Brain Res Bull 2003; 61; 321-326.
113. Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000; 107: 140-147.
114. Hildebrandt M, Rose M, Rüter J, Salama A, Mönnikes H, Klapp BF. Dipeptidylpeptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterology 2001; 10: 1067-1072.
115. Sedo A, Vlasicova K, Bartak P, et al. Quaternary benzo[c]phenanthridine alkaloids as inhibitors of aminopeptidase N and dipeptidyl peptidase IV. Phytother Res 2002; 16: 84-87.
116. Busso N, Wagtmann N, Herling C, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005; 166: 433-442.
117. Juillerat-Jeanneret L, Aubert JD, Leuenberger P. Peptidases in human bronchoalveolar lining fluid, macrophages and epithelial cells: dipeptidylaminopeptidase IV/CD26, aminopeptidase N/CD13 and dipeptidyl carboxypeptidase/angiotensin converting enzyme. J Lab Clin Med 1997; 130: 603-614.
118. Jensen J, Langkilde AR, Fenst C, et al. CD4 T cell activation and disease activity at onset of multiple sclerosis. J Neuroimmunol 2004; 149: 202-209.
119. Khoury SJ, Guttmann CR, Orav FJ, Kikinis F, Jolesz FA, Weiner HL. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol 2000; 57: 1183-1189.
120. Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol 1997; 19: 15-24.
121. Yan SS, Wu ZY, Zhang HP, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration in the central nervous system. Nature Med 2003; 9: 287-293.
122. Steinbrecher A, Reinhold D, Quigley L, et al. Dipeptidyl peptidase IV in inflammatory CNS disease. Adv Exp Biol Med 2000; 477: 145-153.
123. Steinbrecher A, Reinhold D, Quigley L, et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephelomyelitis and up-regulates TGF-β secretion in vivo. J Immunol 2001; 166: 2041-2048.
124. Bristol LA, Bachovchin W, Takacs L. Inhibition of CD26 enzyme activity with Pro-boropro stimulates rat granulocyte/macrophage colony formation and thymocyte proliferation in vitro. Blood 1995; 85: 3602-3609.
125. Gines S, Marino M, Mallol J, et al. Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction. Biochem J 2002; 361: 203-209.
126. Ohnuma K, Yamochi T, Uchiyama M, et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci USA 2004; 101: 14186-14191.
127. Ohnuma K, Yamochi T, Uchiyama M, et al. CD 26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. Mol Cell Biol 2005; 25: 7743-7757.
128. Sato K, Dang NH. CD26: a novel treatment target for T-cell lymphoid malignancies?. Int J Oncol 2003; 22: 481-497.
129. Bauvois B, Sanceau J, Wietzerbin J. Human U937 cell surface peptidase activities: characterization and degradation effects on tumor necrosis factor-alpha. Eur J Immunol 1992; 22: 923-930.
130. Shioda T, Kato H, Ohnishi Y, et al. Anti-HIV and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1 beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 1998; 95: 6331-6336.
131. Christopherson KW, Hangoc C, Broxmeyer HE. Cell surface peptidase CD26/ dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 a-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol 2002; 169: 7000-7008.
132. Guan E, Wang J, Norcross MA. Amino-terminal processing of MIP-1beta/CCLA by CD26/dipeptidyl peptidase IV. J Cell Biochem 2004; 92: 53-64.
133. Proost P, Struyf S, Schols D, et al. Truncation of macrophage-derived chemokine by CD26/dipeptidyl peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999; 274: 3988-3993.
134. Lim JK, Bums JM, Lu W, DeVico AL. Multiple pathways of aminoterminal processing produce two truncated variants of RAN-TES/CCL5. J Leuk Biol 2005; 78: 442-452.
135. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidage IV (CD26)-mediated cleavage. J Exp Med 1997; 186: 1865-1872.
136. Proost P, De Meester I, Schols D, et al. Amino-terminal truncation of chomokines by CD26/dipeptidyl peptidase IV. Conversion of RAN-TES into a potent inhibitor of monocyte chemotaxis and HIV-1 infection. J Biol Chem 1998; 273: 7222-7227.
137. Dimitrijevi M, Stanojevi S, Vuji V, et al. Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral IV Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). J Neuroimmunol, 2002; 129: 35-42.
138. Sanna V, Di Giacomo A, La Cava A, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003; 111: 241-250.
139. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 2000; 96: 1674-1680.
140. Irazusta J, Larrinaga G, Gonzalez-Maeso J, Gil J, Meana JJ, Casis. L. Distribution of prolyl endopeptidase activities in rat and human brain. Neurochem Int 2002; 40: 337-345.
141. O'Leary RM, Gallagher SP, O'Connor B. Purification and characterization of a novel membrane-bound form of prolyl endopeptidase in bovine brain. Int J Biochem. Cell Biol 1996; 29: 441-449.
142. Shan L, Marti T, Sollid LM, Gray GM, Khosla C. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 2004; 383: 311-318.
143. Shan L, Mathews II, Khosla C. Structural and mechanistic analysis of two prolyl endopeptidases: role of interdomain dynamics in catalysis and specificity. Proc Natl Acad Sci USA 2005; 102: 3599-3604.
144. Wilk S, Orlowski M. Inhibition of rabbit brain prolyl endopeptidase by n-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor. J Neurochem 1983; 41: 69-75.
145. Bastos IMD, Grellier P, Martins NF, et al. Molecular, functional and structural properties of the prolyl oligopeptidase of trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. Biochem J 2005; 388: 29-38.
146. Fuxreiter M, Magyar C, Juhasz T, Szeltner Z, Polgar L, Simon I. Flexibilitx of prolyl oligopeptidase: molecular dynamics and molecular framework analysis of the potential substrate pathways. Proteins 2005: 60: 504-512.
147. Vonalainen JI, Jovonen RO, Forsberg MM, et al. Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochem Pharm 2002; 64: 463-471.
148. Demuth HU, Schlenzig D, Schierhorn A, Grosche G, Chapot-Chartier MP, Gripon JC. Design of (omega-N-(O-acyl)hydroxy amid) aminodicarboxylic acid pyrrolidides as potent inhibitors of proline-specific peptidases. FEBS Lett 1993; 320: 23-27.
149. Nakajima T, Ono Y, Kato A, Maeda J, Ohe T. Y-29794, a non-peptide prolyl endopeptidase inhibitor that can penetrate into the brain. Neurosci Lett 1992, 141, 156-160.
150. Kahyaoglu A, Haghjoo K, Kraicsovits F, Jordan F, Polgar L. Benzyloxycarbonyl- prolylprolinal, a transition-state analogue for prolyl oligopeptidase, forms a tetrahedral adduct with catalytic serine, not a reactive cysteine. Biochem J 1997; 372: 839-843.
151. Hermecz I, Kanai K. Prolyl endopeptidase inhibitors. Farmaco 2000; 55: 188-190.
152. Bakker AV, Jung S, Spencer RW, Vinick FJ, Faraci WS. Slow tight-binding inhibition of prolyl endopeptidase by benzyloxycarbonyl-prolyl-prolinal. Biochem J 1990; 271: 559-562.
153. Jarho EM, Venäläinen JI, Juntunen J, et al. An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors. Bioorg Med Chem Lett 2006; 16: 5590-5593.
154. Tarrago, T, Frutos S, Rodriguez-Mias RA, Giralt E. Identification by 19F NMR of traditional Chinese medicinal plants possessing prolyl oligopeptidase inhibitory activity. ChemBioChem 2006; 7: 827-833.
155. Morain P, Lestage P, De Nanteuil G, et al. S17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS Drug Rev 2002; 8: 31-52.
156. Rossner S, Schulz I, Zeitschel U, Schliebs R, Bigl V, Demuth HU. Brain prolyl endopeptidase expression in aging, APP transgenic mice and Alzheimer's disease. Neurochem Res 2005; 30: 695-702.
157. Schulz I, Zeitschel U, Rudolph T, et al. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem 2005; 94: 970-979.
158. Schulz I, Gerhartz B, Neubauer A, et al. Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur J Biochem 2002; 269: 5813-5820.
159. Mantle D, Flakous G, Ishiura S, Blanchard PJ, Perry EK. Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. Clin Chim Acta 1996; 249: 129-139.
160. Maes M, Goossens F, Scharpe S, Calabrese J, Desnyder R, Meltzer HY. Alterations in plasma prolyl endopeptidase activity in depression, mania and schizophrenia: effects of anti-depressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 1995, 58: 217-225.
161. Yoshimoto T, Kado K, Matsubara F, Koriyama N, Kaneto H, Tsuru D. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effects. J Pharmacobiodyn 1987; 10: 730-735.
162. Schneider JS, Giardinière M, Morain P. Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MTP-treated monkeys. Neuropsychopharmacology 2002; 26: 176-182.
163. Kovacs GL, De Wied D. Peptidergic modulation of learning and memory processes. Pharmacol Rev 1994; 46: 269-291.
164. Toide K, Shinoda M, Fujiwara T, Iwamoto Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol Biochem Behav, 1997; 56: 427-434.
165. Bellemère G, Morain P, Vaudry H, Jégou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and α-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem 2003; 84: 919-929.
166. Shinoda M, Toide K, Ohsawa I, Kohsaka S. Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid β protein in NG108-15 cells. Biochim Biophys Res Comm 1997; 235: 641-645.
167. Kato A, Fukunari A, Sakai Y, Nakajima T. Prevention of amyloid-like deposition by a selective prolyl endopeptidase inhibitor, Y-29794, in senescence-accelerated mouse. J Pharm Exp Ther 1997; 283: 328-335.
168. Petit A, Barelli H, Morain P, Checler F. Novel proline endopeptidase inhibitors do not modify Abeta-40/42 formation and degradation by human cells expressing wild-type and mutated beta-amyloid precursor protein. Br J Pharmol 2000; 130: 1613-1617.
169. Laitinen KS, von Groen T, Tanila H, Venäläinen J, Männistö PT, Alafuzoff I. Brain prolyl oligopeptidase activity is associated with neuronal damage rather than β-amyloid accumulation. Neuroreport 2001; 12: 3309-33312.
170. Portevin B, Benoist A, Rémond G, et al. New prolyl endopeptidase inhibitors: in vitro and in vivo activities of azabicyclo[2.2.2]octane, azabicyclo[2.2.1]heptane and perhydroindole derivatives. J Med Chem 1996; 39: 2379-2391.
171. Toide K, Shinoda M, Iwamoto Y, Fujiwara T, Okamiya K, Uemura A. A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res 1997; 83: 147-151.
172. Katsube N, Sunaga K, Aishita H, Chuang DM, Ishitani R. ONO-1603, a potential antidementia drug, delays age-induced apoptosis and suppresses overexpression of glyceraldehyde-3-phosphate dehydrogenase in cultured central nervous system cells. J Pharm Exp Ther 1999; 288: 6-13.
173. Jiang CH, Tsien JZ, Schultz PG, Hu Y. The effects of aging on gene expression in the hypothalamus and cortex of mice. Proc Natl Acad Sci USA 2001; 98: 1930-1934.
174. Fukunari A, Kato A, Sakai Y, et al. Colocalization of prolyl endopeptidase and amyloid β-peptide in brains of senescence-accelerated mouse. Neurosci Lett 1994; 176: 201-204.